文献速递主动脉疾病

Gore全球血管内主动脉治疗注册研究中胸主动脉腔内修复术治疗B型夹层患者的结果

Outcomes from the Gore Global Registry for Endovascular Aortic Treatment in patients undergoing thoracic endovascular aortic repair for type B dissection.
PubMed 文献 · J Vasc Surg · 2018-06-23

基于GREAT前瞻性多中心注册研究,分析264例B型主动脉夹层患者接受胸主动脉腔内修复术的结果。急性非复杂性夹层患者总体生存率显著优于其他类型,近端锚定区直径>40 mm与逆行性A型夹层风险增加相关,左锁骨下动脉覆盖和/或血运重建与主动脉事件风险增加相关。

要点

  • 急性非复杂性B型夹层患者2年总体生存率93%,显著优于其他类型夹层的83%。
  • 近端锚定区直径>40 mm者逆行性A型夹层发生率为18%,而≤40 mm者为2%。
  • 左锁骨下动脉覆盖者主动脉事件发生率约为未覆盖者的2倍。

核心结论

  • 使用conformable GORE TAG胸主动脉内假体装置对B型主动脉夹层行胸主动脉腔内修复术,主动脉死亡和并发症发生率低。
  • 急性非复杂性B型夹层患者死亡率显著低于其他患者。
  • 较大的近端锚定区与更频繁的逆行性A型夹层相关。
  • 左锁骨下动脉受累(覆盖和/或血运重建)与随访期间主动脉事件风险增加相关。

研究设计与样本

  • GREAT为前瞻性多中心注册研究,收集W. L. Gore主动脉内假体性能的真实世界数据。
  • 2010年至2016年,来自4大洲14个国家113个中心的超过5000例患者入组GREAT。
  • 研究人群为因B型主动脉夹层接受治疗的患者,共264例(80%男性,平均年龄62岁),其中急性170例(64%)、慢性94例(36%)。

主要发现

  • 慢性B型夹层患者所需内假体覆盖长度显著长于急性B型夹层患者(P = .05)。
  • 早期术后并发症发生于9%的患者,慢性与急性夹层间无差异(P = .11)。
  • 30天主动脉死亡率和全因死亡率分别为1.5%和2.3%,基于慢性性无差异。
  • 平均随访26个月期间,总主动脉死亡率为2.7%,总全因死亡率为12.5%。
  • 慢性B型夹层全因死亡率显著高于急性B型夹层(19.2% vs 8.8%,P = .02)。

关键数值与推荐

  • 多变量分析显示,急性非复杂性夹层患者2年总体生存率93%,其他类型夹层为83%(P < .05)。
  • 近端锚定区直径>40 mm与逆行性A型夹层风险增加相关(18% vs 2%,P = .02)。
  • 左锁骨下动脉覆盖患者主动脉事件发生率约为未覆盖患者的2倍(P < .01)。
  • 左锁骨下动脉血运重建患者主动脉事件发生率约为覆盖但未血运重建患者的1.5倍(P = .04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Global Registry for Endovascular Aortic Treatment (GREAT) is a prospective multicenter registry collecting real-world data on the performance of W. L. Gore (Flagstaff, Ariz) aortic endografts. The purpose of the present study was to analyze the implementation and outcomes of thoracic endovascular aortic repair (TEVAR) in GREAT patients with type B aortic dissection (TBAD). METHODS: From 2010 to 2016, >5000 patients were enrolled in the GREAT from 113 centers in 14 countries across 4 continents. The study population comprised those treated for TBAD. The primary outcomes of interest were mortality and freedom from aortic events (AEs). RESULTS: A total of 264 patients (80% male; mean age, 62 years) underwent TEVAR for the treatment of 170 (64%) acute and 94 (36%) chronic cases of TBAD. Chronic TBAD patients required significantly longer endograft coverage than did acute TBAD patients (P = .05). Early postoperative complications occurred in 9% of patients, with no difference in chronic vs acute dissection (P = .11). The 30-day aortic mortality and all-cause mortality were 1.5% and 2.3%, respectively, with no differences based on chronicity. During a mean follow-up of 26 months, the total aortic mortality was 2.7% and the total all-cause mortality was 12.5%. The all-cause mortality was significantly greater for chronic vs acute TBAD (19.2% vs 8.8%, respectively; P = .02). On multivariate analysis, patients with acute uncomplicated dissections had significantly improved overall survival compared with all other categories of dissections (93% vs 83% at 2 years; P < .05). A proximal landing zone diameter >40 mm was associated with an increased risk of retrograde type A dissection (18% vs 2%; P = .02). Patients undergoing left subclavian artery (LSA) coverage experienced a twofold greater rate of AEs compared with noncoverage patients (P < .01). Patients who underwent LSA revascularization experienced a 1.5-fold greater rate of AEs compared with patients covered without revascularization (P = .04). CONCLUSIONS: TEVAR for TBAD using the conformable GORE TAG thoracic endoprosthesis device can be performed with a low incidence of aortic mortality and complications. Acute uncomplicated TBAD patients had a significantly lower mortality rate than that of other patients. Larger proximal landing zones were associated with more frequent retrograde type A dissection. LSA involvement (coverage and/or revascularization) was associated with an increased risk of AEs during follow-up.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tjaden BL, Sandhu H, Miller C, et al. Outcomes from the Gore Global Registry for Endovascular Aortic Treatment in patients undergoing thoracic endovascular aortic repair for type B dissection. J Vasc Surg. 2018. PMID: 29941315. doi:10.1016/j.jvs.2018.03.391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。